Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-resistant and -dependent Nephrotic Syndrome: Multicentric Report

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2010 Aug 28

PMID 20798255

Citations 91

Authors

Ashima Gulati

Aditi Sinha

Stanley C Jordan

Pankaj Hari

Amit K Dinda

Sonika Sharma

Rajendra N Srivastava

Asha Moudgil

Arvind Bagga

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: The treatment of idiopathic nephrotic syndrome is often complicated by a refractory and relapsing course, with risk of drug toxicity and progressive renal failure. We report the efficacy and safety of rituximab in patients with steroid-resistant (SRNS) and steroid-dependent nephrotic syndrome (SDNS) refractory to standard therapy.

Design, Setting, Participants, & Measurements: This was a cohort study in academic, tertiary care centers in India and the United States. Patients with SRNS or SDNS, not responding to medications or showing calcineurin inhibitor toxicity, treated with two to four doses of intravenous rituximab, and followed ≥12 months were included. Remission was termed as complete, partial, or no response.

Results: Thirty-three patients with SRNS (24 initial, 9 late resistance) and 24 with SDNS, with mean ages of 12.7 ± 9.1 and 11.7 ± 2.9 years, respectively, were included. Six months after rituximab therapy, 9 (27.2%) patients with SRNS showed complete remission, 7 (21.2%) had partial remission, and 17 (51.5%) had no response. At 21.5 ± 11.5 months, remission was sustained in 15 (complete: 7, partial: 8) patients. Of 24 patients with SDNS, remission was sustained in 20 (83.3%) at 12 months and in 17 (71%) at follow-up of 16.8 ± 5.9 months. The mean difference in relapses before and 12 months after treatment with rituximab was 3.9 episodes/patient per year.

Conclusions: Therapy with rituximab was safe and effective in inducing and maintaining remission in a significant proportion of patients with difficult SRNS and SDNS.

Citing Articles

Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up.

Ivanov D, Weber L, Levtchenko E, Vakulenko L, Ivanova M, Zavalna I Biomedicines. 2024; 12(11).

PMID: 39595166 PMC: 11592163. DOI: 10.3390/biomedicines12112600.

Rituximab versus tacrolimus as corticosteroid-sparing therapy for children with steroid-dependent nephrotic syndrome: A systematic review and meta-analysis of randomized and nonrandomized controlled trials.

Ang J, Widjanarko N, Ekaputra A Tzu Chi Med J. 2024; 36(3):319-329.

PMID: 38993828 PMC: 11236076. DOI: 10.4103/tcmj.tcmj_234_23.

Kidney outcomes in children with primary focal segmental glomerulosclerosis from a low- and middle- income country.

Priyanka K, Deepthi B, Krishnasamy S, Ganesh R, Sravani M, Krishnamurthy S Pediatr Nephrol. 2024; 39(12):3485-3495.

PMID: 38652137 DOI: 10.1007/s00467-024-06382-w.

Steroid-resistant minimal change nephrotic syndrome associated with thymoma treated effectively with rituximab following thymectomy and cyclosporine: a case report.

Watanabe Y, Hirai K, Hirata M, Kitano T, Ito K, Ookawara S BMC Nephrol. 2024; 25(1):53.

PMID: 38336671 PMC: 10858521. DOI: 10.1186/s12882-024-03485-2.

Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial).

Nozu K, Sako M, Tanaka S, Kano Y, Ohwada Y, Morohashi T Clin Exp Nephrol. 2023; 28(4):337-348.

PMID: 38010466 PMC: 10955017. DOI: 10.1007/s10157-023-02431-0.

References

Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-LE Camus C, Afanetti M . Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23(8):1269-79. DOI: 10.1007/s00467-008-0814-1. View

Boumans M, Tak P . Rituximab treatment in rheumatoid arthritis: how does it work?. Arthritis Res Ther. 2009; 11(6):134. PMC: 3003538. DOI: 10.1186/ar2852. View

Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y . Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010; 25(3):539-44. DOI: 10.1007/s00467-009-1377-5. View

Kushner R, Weinsier R . Evaluation of the obese patient. Practical considerations. Med Clin North Am. 2000; 84(2):387-99, vi. DOI: 10.1016/s0025-7125(05)70227-3. View

Lands L . New therapies, new concerns: rituximab-associated lung injury. Pediatr Nephrol. 2010; 25(6):1001-3. DOI: 10.1007/s00467-010-1476-3. View

Li X, Li H, Ye H, Li Q, He X, Zhang X . Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis. 2009; 54(1):51-8. DOI: 10.1053/j.ajkd.2009.02.018. View

Chaumais M, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E . Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009; 24(9):1753-5. DOI: 10.1007/s00467-009-1195-9. View

Sellier-Leclerc A, Macher M, Loirat C, Guerin V, Watier H, Peuchmaur M . Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010; 25(6):1109-15. DOI: 10.1007/s00467-010-1465-6. View

Mok C . Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum. 2006; 36(2):71-81. DOI: 10.1016/j.semarthrit.2006.04.008. View

10.

Dorner T, Kinnman N, Tak P . Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther. 2010; 125(3):464-75. DOI: 10.1016/j.pharmthera.2010.01.001. View

11.

Liptak P, Ivanyi B . Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol. 2006; 2(7):398-404. DOI: 10.1038/ncpneph0225. View

12.

McDonald V, Manns K, Mackie I, Machin S, Scully M . Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010; 8(6):1201-8. DOI: 10.1111/j.1538-7836.2010.03818.x. View

13.

Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M . Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol. 2007; 23(3):481-5. DOI: 10.1007/s00467-007-0640-x. View

14.

Anderson D, Grillo-Lopez A, Varns C, Chambers K, Hanna N . Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans. 1997; 25(2):705-8. DOI: 10.1042/bst0250705. View

15.

Bagga A, Sinha A, Moudgil A . Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007; 356(26):2751-2. DOI: 10.1056/NEJMc063706. View

16.

Haffner D, Fischer D . Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol. 2009; 24(8):1433-8. DOI: 10.1007/s00467-009-1226-6. View

17.

Carson K, Evens A, Richey E, Habermann T, Focosi D, Seymour J . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113(20):4834-40. PMC: 2686134. DOI: 10.1182/blood-2008-10-186999. View

18.

Kyrieleis H, Lowik M, Pronk I, Cruysberg H, Kremer J, Oyen W . Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009; 4(10):1593-600. PMC: 2758253. DOI: 10.2215/CJN.05691108. View

19.

Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E . Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol. 2009; 24(8):1525-32. DOI: 10.1007/s00467-009-1138-5. View

20.

Abeyagunawardena A, Sebire N, Risdon R, Dillon M, Rees L, Vant Hoff W . Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol. 2006; 22(2):215-21. DOI: 10.1007/s00467-006-0264-6. View